Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Evaluation of quality of life measured by change in the DLQI score
研究概览
简要总结
Hailey Hailey and Darier disease are rare genetic dermatoses. Mutations of 2 genes (ATP2C1 or ATP2A2 respectively) are responsible for the diseases. These genes have a key role in calcium pump; their defect create abnormal link between keratinocytes' desmosomes and induce skin lesions. Clinically, patients present with inflammatory lesions located in the folds. Quality of life is impaired because of pain, pruritus and tendency to infections. Lesions are permanent but acute exacerbations occur in hot seasons because of increased sweating. Usual therapies are often not effective (local treatment, laser, phototherapy). Because sweating is a well established inducing or aggravating factor, botulism toxin could be an effective treatment for these diseases.
Botulism toxin is already used in clinical practice and acts via a decreased sweet secretion. Improvement of skin lesions in Hailey-Hailey or Darier diseases has been previously reported in a few cases but there is no study properly evaluating the benefit of such treatment.
The aim of the project is to study the improvement of quality of life for patients suffering from Hailey-Hailey or Darier diseases after a injections of botulism toxin in large skin folds. The principal objective is to estimate the distribution of the variation of quality of life at M1 vs. baseline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis (clinical and histological features) of Hailey Hailey or Darier diseases.
- •Moderate to very severe lesions located in large folds
- •Patient aged 18 ans or more
- •Patient with health coverage
- •Patient who have signed the consent form
- •Patient proficient into filling out the questionnaires.
排除标准
- •Hypersensibility to toxin or excipients
- •Myastheny
- •Deglutition's problems
- •Past medical history of dysphagia or aspiration pneumonia
- •Pregnancy (positive B-HCG test performed a maxima 72h before) or breastfeeding
- •Mental , physical incapacity to fill in the questionnaires
- •Guardianship patients
- •Skin infections at the inclusion visit
- •Application in the last 7 days at the site of injection of local treatments (apart emollients or antiseptics) or injections of botulism toxin or dynamic phototherapy or laser in the last 6 months.
- •Systemic treatment with aminosides in the last 15 days
- •Inclusion in another study in the last 2 months.
研究组 & 干预措施
Botulism Toxin treatment
Injection of 50 UI Botulism toxin for the treated zone
干预措施: Botulism Toxin Treatment (Drug)
结局指标
主要结局
Evaluation of quality of life measured by change in the DLQI score
时间窗: Day 0 and day 30
Variation of DLQI score between Baseline and M1
次要结局
- Evaluation of psychosocial impairment measured by change in the HidroQoL score(Day 0 and Day 180)
- Evaluation of quality of life measured by change in the DLQI score(Day 0 and day 180)
- Evaluation of psychosocial impairment at measured by change in the HidroQoL score(Day 0 and Day 30)
- Evaluation of patient treatment acceptability using visual analogic pain scale(Day 0 after injection)
- Evaluation of long term efficacy as assessed by delay for significant relapse (reappearance of skin lesions justifying treatment)(Up to 180 days)
- Evaluation of skin improvement in treated areas using change the IGA score(Day 0 and Day 180)
- Evaluation by the investigator of the treated lesions global severity change as assessed by comparison using measurement of the affected area(Day 0 and Day 180)
- Evaluation of patient's satisfaction Using the IGA score " Improvement Global Assessment "(Day 180)
- Evaluation of acceptability over the medium to long term as assessed by occurence of side effects(Day 180)
- Evaluation of long term efficacy as assessed by percentage of non-responder patients with IGA score egal to 0(Day 30)
- Evaluation of long term efficacy as assessed by comparison between the number of infection episodes occurred during the 6 months before the study or during the 6 months of the study(Up to 180 days)